Literature DB >> 9178176

Oral candidiasis in HIV infection: predictive value and comparison of findings in injecting drug users and homosexual men.

J A Phelan1, M D Begg, I B Lamster, J Gorman, D Mitchell-Lewis, R D Bucklan, W M el-Sadr.   

Abstract

The objectives of this study were to compare the relationship of oral candidiasis to HIV status, cohort and CD4+ lymphocyte values in injecting drug users and homosexual men and to examine its impact on prognosis. An oral examination was added to an ongoing longitudinal study of HIV infection. Data obtained at 6-month intervals included smoking, illicit drug use, medication use, symptoms and medical diagnoses, physical examination findings and laboratory data. In this study HIV+ subjects were much more likely to present with oral candidiasis than were HIV- subjects (OR = 6.3, P < 0.01). Injecting drug users, regardless of serostatus, were more likely than homosexual men to present with oral candidiasis (OR = 3.0, P = 0.001). In both cohorts oral candidiasis was associated with low CD4+ lymphocyte counts and percent ages, and Kaplan-Meier survival estimates showed that subjects with oral candidiasis had a poorer prognosis than those without candidiasis, even after controlling for CD4+ lymphocyte count.

Entities:  

Mesh:

Year:  1997        PMID: 9178176     DOI: 10.1111/j.1600-0714.1997.tb01230.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  2 in total

1.  Intercellular adhesion molecule 1-dependent activation of interleukin 8 expression in Candida albicans-infected human gingival epithelial cells.

Authors:  Hiroshi Egusa; Hiroki Nikawa; Seicho Makihira; Anahid Jewett; Hirofumi Yatani; Taizo Hamada
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Recovery of Candida dubliniensis and other yeasts from human immunodeficiency virus-associated periodontal lesions.

Authors:  M A Jabra-Rizk; S M Ferreira; M Sabet; W A Falkler; W G Merz; T F Meiller
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.